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Abstract 
There is heightened recognition of the public health implications of anabolic androgenic 
steroids (AAS) for the use of image and performance enhancement; with increasing 
evidence of their long-term negative health impacts, the hazards associated with their 
administration (often via injection), and the variability and unpredictability of their contents. In 
order to optimise the effects of these drugs, together with strict dietary and training regimes, 
AAS users typically supplement their use with an expansive and continually evolving range 
of ancillary drugs. The discovery and subsequent adoption of these drugs by the broader 
AAS user population is largely dependent upon a minority of social influencers within the 
bodybuilding community. 
Pioneering enhanced bodybuilders who self-experiment with a diverse range of image and 
performance enhancing drugs (IPEDs) and ancillary drugs have been the forerunners in the 
development of an underground user-led literature, online discussion forums, and were early 
adopters of internet-facilitated drug markets. Yet the impact of their self-experimentations 
extends well beyond the enhanced bodybuilding community, particularly in their use of 
ancillary drugs.  
Most significantly has been their role in the diffusion of various enhancement and 
psychoactive drugs to the wider population. Using the theoretical framework of the 'diffusion 
of innovation' we consider the role that pioneering enhanced bodybuilders have played in the 
diffusion of various enhancement and psychoactive drugs to the wider population through a 
focus on three substances –dinitrophenol (DNP), melanotan II and gamma-hydroxybtyrate 
(GHB). With an increasing range of drugs used by bodybuilders, coupled with an expansion 
in the use of online forums and online platforms to purchase pharmacological and new 
psychoactive drugs, we anticipate this trend of diffusion amongst the wider population will 
continue to flourish. Therefore, we highlight the need for policy makers to monitor emergent 
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The following commentary reviews the case for and the evidence to support the public health 
surveillance of AAS users and particularly the pioneering influential innovators within their 
community whom we term “enhanced bodybuilders”. In a departure from traditional calls to 
policy makers for the monitoring of AAS users (Hope, McVeigh et al. 2013, Iversen, Topp et 
al. 2013), we employ the concept of 'diffusion of innovation' in looking beyond the immediate 
health protection and harm reduction of the users to consider the potential value to the wider 
drug using populations.  
Anabolic androgenic steroids as a public health concern 
The use of anabolic androgenic steroids (AAS) is now considered a significant global public 
health policy issue (Evans-Brown, McVeigh et al. 2012, Kanayama, Kaufman et al. 2018). 
Prevalence of AAS is difficult to determine, nevertheless global prevalence has been 
estimated at levels as high as 3.3% (Sagoe, Molde et al. 2014), with other scholars 
suggesting that approximately 3 million men have used AAS in the United States alone 
(Pope, Kanayama et al. 2014). Whilst relatively high levels of AAS use have been identified 
in the United States, Australia and Northern Europe for several decades, usage at high 
levels has recently been identified in other regions such as South America and the Middle 
East (Abrahin, Sousa et al. 2014, Zahnow, McVeigh et al. 2017, Sagoe and Pallesen 2018, 
Hearne, Wazaify et al. 2020). In addition to the estimated numbers of users, recent studies 
have identified diverse populations of AAS users in relation to both characteristics and 
motivations for use, ranging from the unplanned, hedonistic user through to the expert 
enhanced bodybuilder (Christiansen, Vinther et al. 2016, Zahnow, McVeigh et al. 2018).  
The major cause for concern regarding AAS is their association with a range of adverse 
health conditions and associated morbidity and mortality. Summarised in the Endocrine 
Statement of 2014, AAS are associated with harms to many of the body’s systems including 
cardiovascular effects, hematologic effects, psychiatric and neuropsychologic effects, and 
hormonal and metabolic effects (Pope, Wood et al. 2014). As we enter the 2020s, we have 
increasing data to evidence the long-term effects of AAS use. The potential for cardiac 
damage highlighted during the 1980s and 1990s (Mochizuki and Richter 1988, Herschman 
1990, Hartgens, Kuipers et al. 1996) has been realised in the form of increased case reports 
(Baggish, Weiner et al. 2017, Doleeb, Kratz et al. 2019) and analyses of post mortem data 
(Sculthorpe, Grace et al. 2010, Montisci, El Mazloum et al. 2012, Pope, Wood et al. 2014). 
Additionally, hypogonadism has been identified as a significant health issue for many 
sustained AAS users (Karavolos, Reynolds et al. 2015), requiring clinical interventions 
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(Street and Scally 2000, Tan and Vasudevan 2003, Rahnema, Lipshultz et al. 2014). 
Perhaps the most significant and concerning is the emerging evidence of the adverse effects 
of long-term AAS use in relation to the brain. Whilst it has long been acknowledged that AAS 
can result in psychiatric symptoms (Perry, Yates et al. 1990, Pope and Katz 1992, Su, 
Pagliaro et al. 1993), such symptoms appear to be at least in part dose-dependent (Hall, Hall 
et al. 2005) and largely idiosyncratic (Pope, Wood et al. 2014). However, recent studies 
have identified structural changes to the brain (Bjornebekk, Walhovd et al. 2017, Westlye, 
Kaufmann et al. 2017) with associated cognitive impairment (Bjornebekk, Westlye et al. 
2019, Hauger, Westlye et al. 2019).  
The adverse effects of AAS alone provides a compelling case for policy makers to develop 
public health surveillance of this population, in order to protect and promote their health and 
well-being. Further evidence to support the monitoring and surveillance can be found in the 
findings from research in the United Kingdom related to blood borne viruses. Prevalence of 
HIV and hepatitis C are considerably higher amongst AAS users than that found in the 
general population (Hope, McVeigh et al. 2013, Hope and Iversen 2019), with HIV levels 
shown to be on a par with those injecting heroin (Hope, Harris et al. 2016). While the route of 
transmission, via sex or injecting behaviours together with the timing of infection (potentially 
prior to AAS use) remains uncertain (Underwood 2019), and sharing of injecting equipment 
rare when compared to people who inject psychoactive drugs (Van Beek 2015), the fact 
remains that there are significant numbers of HIV positive men amongst some populations of 
AAS users and this is a public health concern (Iversen, Topp et al. 2013, Iversen, Hope et al. 
2016, McVeigh, Kimergard et al. 2016, McVeigh 2019). Further evidence indicates low levels 
of users’ knowledge related to positive hepatitis C status (Hope, McVeigh et al. 2017) and 
low uptake of blood borne virus testing amongst AAS injectors (Rowe, Berger et al. 2017, 
Hope and Iversen 2019) with the exception of gay and bisexual men. In the main, AAS using 
populations consist largely of men, with high levels of sexual activity and low condom use, 
regardless of sexual orientation (Ip, Yadao et al. 2017, Hope and Iversen 2019, Ip, 
Doroudgar et al. 2019). Furthermore, AAS results in an increase in libido for many (Begley, 
McVeigh et al. 2017, Kees 2019, Pereira, Moyses et al. 2019) and for others the use of 
drugs such as PDE5i to treat erectile dysfunction (Llewellyn 2017), potentially compounding 
sexual risk behaviours and warranting public health monitoring. 
Further evidence supporting the monitoring of the AAS user population stems from their high 
levels of polypharmacy (Sagoe, McVeigh et al. 2015, Salinas, Floodgate et al. 2019), both in 
the pursuit of muscular enhancement and concomitant psychoactive drug use, particularly 
cocaine (Dodge and Hoagland 2011, Hope, McVeigh et al. 2013, Salinas, Floodgate et al. 
2019). A recent study in Norway reported that 28% of patients being treated for substance 
4 
 
use disorders had used AAS (Havnes, Jorstad et al. 2020), levels that are considerably 
higher than previous research in the United States (Kanayama, Cohane et al. 2003). Yet 
AAS use is often poorly recognised and inadequately addressed within treatment settings 
(Havnes and Skogheim 2019) with AAS users at times using these drugs as self-directed 
treatment for the adverse effects of opiate dependence (Havnes, Jorstad et al. 2020). This 
polypharmacy clearly requires ongoing investigation. 
This growing body of evidence indicates a need for policy makers to establish robust 
monitoring of this population, to systematically identify and monitor harms experienced by 
users, and to facilitate the evaluation of interventions. These diverse interventions may aim 
to prevent or delay initiation into AAS use, mitigate or reduce the harms of use, support the 
treatment, cessation and relapse prevention or monitor associated behaviours related to sex 
or psychoactive use.  Further still, a case for surveillance may be made because of the 
potential harms posed to others in the forms of psychopharmacological crime and market 
crimes (Goldstein 1985) but these arguments sit beyond the scope of this commentary.  
The bigger picture: Enhanced bodybuilders, innovation and diffusion 
Beyond the evidence of the need to monitor the effects of AAS use on the individual or the 
wider community, we argue here that there is evidence to support the monitoring of the 
pioneering enhanced bodybuilders who exert influence on the wider communities of AAS 
users. It is these innovators that may be considered a “sentinel population”, a group of highly 
influential individuals who may act as an “early warning system” related to emerging drug 
practices. Everett Rogers’ work on the diffusion of innovations  (Rogers 1983, Rogers 1995) 
provides a framework with which to understand how certain drug using practices of 
enhanced bodybuilders may be disseminated largely via the internet beyond the 
bodybuilding culture to the general population. While by no means a new theory (De Tarde 
1903), diffusion theory has evolved over time having been influenced by research into mass 
communication in the 1950s (Katz, Lazersfeld et al. 2017). The model explains how a “trickle 
down” effect accelerates, as knowledge, attitudes and behaviours are passed from a small 
group of innovators, to a larger group of early adopters to the (early and late) majority and 
finally the “laggards” (Rogers, 1983). In the case of AAS and ancillary drugs, this process 
manifests itself in the following way: (i) influential pioneering bodybuilders self-experiment 
with certain novel drugs and then advocate their use via online platforms; (ii) enhanced 
competitive bodybuilders and certain dedicated gym enthusiasts are “early adopters” of 
these drugs; (iii) their use gains traction amongst the wider dedicated gym training 
community (the “early majority”) (iv) before diffusing out amongst the general population (the 
“late majority” and “laggards”). The theory has been effectively applied to the UK’s 
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phenomenon of Novel Psychoactive Substances (NPS) (Sumnall, Evans-Brown et al. 2011), 
within a sophisticated online society (Corazza, Parrott et al. 2017) and appears particularly 
applicable to the current context in which enhanced bodybuilders can generate a massive 
online following (Underwood 2017, Underwood and Olson 2018) 
Many of the common practices adopted by enhanced bodybuilders can be traced back to the 
1980s and early 1990s and the pioneering work of authors such as Dan Duchaine (Duchaine 
1982, Duchaine 1989, Duchaine 1996) and Bill Phillips (Phillips 1991). Duchaine’s 
Underground Steroid Handbooks are credited as being the most influential within 
bodybuilding circles. As well as being infamous with the authorities, criminal justice 
organisations and policy makers (Berg 2011), he came to the general public’s attention in 
1988, on the front page of the New York Times with the headline: “A guru who spreads the 
gospel of steroids” (Alfano and Janofsky 1988).  
Dinitrophenol (DNP) is a prime example of a drug that can be observed as having been used 
across multiple diverse settings, including amongst enhanced bodybuilders. The origins of 
DNP can be traced back to the early 20th century with the identification of adverse effects 
stemming from its use in the manufacturing of munitions  (Barral 1916, Perkins 1919, Evans-
Brown, McVeigh et al. 2012). DNP’s potential as a weight loss medication were soon 
realised, but cut short after the drug was banned in the 1930s following the identification of 
severe adverse effects, including fatalities (Evans-Brown, McVeigh et al. 2012). Dan 
Duchaine is credited with bringing this powerful weight loss product to the attention of the 
enhanced bodybuilding community (Baker 1997). However, the subsequent expansion of 
interest and adoption of DNP as an image and performance enhancing aid has largely been 
driven by the internet and its promotion through AAS online outlets and its marketing as an 
effective slimming aid (McVeigh, Germain et al. 2017). These digital mediums helped 
elevate the use of this metabolic poison from a limited number of enhanced bodybuilders 
who reported sporadic adverse effects (Grundlingh, Dargan et al. 2011) to fatalities amongst 
vulnerable and naive sections of the general population, seeking an easy weight loss 
solution (Kamour, George et al. 2015, Petroczi, Ocampo et al. 2015). 
Secondly, it is possible to chart similar instances of diffusion by examining the growth of 
melanotan II, a relatively new drug with properties that mimic the effects of exposure to the 
sun, whilst also reportedly inducing penile erections and increasing sexual desire and weight 
loss (Hadley and Dorr 2006). While much of the concerns regarding melanotan II has 
centred around its injection by naïve users (Van Hout and McVeigh 2019), even with the 
development and promotion of a nasal formulation, there remains evidence of adverse 
consequences, such as renal infarction and systemic toxicity (Peters, Hadimeri et al. 2020) 
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(Nelson, Bryant et al. 2013) and most commonly changes to the skin such as the 
development of melanoma (Paurobally, Jason et al. 2011, Hjuler and Lorentzen 2014). 
Competitive bodybuilders who sought all-over tans to help enhance the aesthetic of their 
muscular definitions were early adopters of this drug, yet its use rapidly filtered down to other 
AAS users and was observed among service users of needle and syringe programmes in 
the United Kingdom (Evans-Brown, Dawson et al. 2009). Though melanotan II’s diffusion 
from the enhanced bodybuilding population to a wider “injecting naïve” population was 
predictable, responses were slow and inadequate (Van Hout and McVeigh 2019).   
Thirdly, gamma-hydroxybutyrate (GHB) is an example of a substance again promoted by 
Duchaine (Assael 2007) and subsequently adopted by different populations within diverse 
settings, for different intended purposes. First developed in the 1960s for use as an 
anaesthetic, its use as an image and performance enhancing aid was popularised by 
Duchaine in the 1980s who used GHB to promote the release of growth hormone and thus 
enhance muscularity.  
The rationale behind the adoption of GHB was its ability to induce deep, prolonged, slow-
wave sleep, which was essential in the body’s production of growth hormone (Mamelak, 
Escriu et al. 1977). Whilst adverse effects and issues of dependence were reported amongst 
enhanced bodybuilders (Hart 2001) the drug gained popularity with a much wider audience 
in the nightclub scene (McCambridge, Mitcheson et al. 2005), where the drug was 
sometimes referred to as “G” or  “Liquid Ecstasy”. Use of the drug continued unabated 
despite a number of deaths due to overdose and dependence with potentially severe 
withdrawal symptoms (Busardo and Jones 2015). GHB has been identified as one of the 
main drugs used by men who have sex with men in the “chemsex” scene (Bourne, Reid et 
al. 2015, Giorgetti, Tagliabracci et al. 2017). GHB  is also associated with drug facilitated 
sexual assaults (ACMD 2007, Olszewski 2008), and while the true extent of the role of GHB 
in these cases has been questioned (Beynon, McVeigh et al. 2008, Nemeth, Kun et al. 
2010), high profile cases of serial sexual assault and murders have brought renewed 
attention to the drug (BBC News 2016, Saud 2020).  
Here, we have illustrated how enhanced body builders are a sentinel population that should 
be monitored, with the three case studies highlighting the strong likelihood of future cases 
occurring. The early identification of diffusion would support effective interventions, perhaps 
averting some the harms that have occurred in the cases of dinitrophenol (DNP), and 
gamma-hydroxybutyrate (GHB). With hindsight the diffusion of many drug using practices 
appears predictable and perhaps even inevitable. Yet there are many other drugs that have 
not seen this pattern of diffusion, despite having the potential to appeal to a much wider 
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population than simply enhanced bodybuilders. Drugs such as clenbuterol, a β₂-agonist, has 
been popular amongst AAS users since the 1980s (Duchaine 1989, Phillips 1991, Llewellyn 
2017). The drug is associated with both weight loss and muscular gains, but without the 
adverse effects of hormonal imbalance that are experienced with AAS. While occasional 
media reports highlight its appeal to those looking to lose weight – with headlines such as 
“Clenbuterol: The new weight-loss wonder drug gripping Planet Zero”(Guest 2007) – its use 
is far from widespread and reports of adverse effects of those using outside the enhanced 
bodybuilding community are rare. Similarly, human chorionic gonadotrophin (hCG) has long 
been a key element of AAS user’s “stack” of drugs (Duchaine 1989, Phillips 1991, Llewellyn 
2017). With properties that stimulate the production of testosterone, it has also been 
promoted as a weight loss product to a wider audience. Such promotion has occurred online 
https://hcgchica.com/buy-hcg-injections-worldwide/ (accessed 1st April 2020) and within 
“infomercials” that extoll its properties of rapid weight loss, reduction of cellulite, sleep 
promotion https://www.fox17online.com/2018/02/06/lose-weight-with-hcg-injections-from-
skin-envy (accessed 1st April 2020). However, once again, this drug failed to gain a footing 
beyond the enhanced bodybuilding community. Why clenbuterol or hCG have not diffused to 
the wider general population, or if they will in the future, is unclear but without the systematic 
monitoring of online forums and marketplaces and engagement with the enhanced 
bodybuilding communities, it is likely that diffusion would result in harms to the wider 
populations before public health responses could be mobilised. 
While anabolic androgenic steroids and human growth hormone remain the mainstay of 
enhanced bodybuilding, new drugs are constantly added to the repertoire of enhancement 
products. Some drugs become a fixture within their pharmacopeia, whilst the popularity of 
other drugs is often short lived. For example nalbuphine – an opioid promoted by “the steroid 
guru” Dan Duchaine –  became popular in the 1990s and resulted in dependence amongst 
some AAS users, yet fell out of fashion over ensuing years (Cohen, Collins et al. 2007, 
Begley, McVeigh et al. 2017) without diffusing to wider society.  Many of the pharmaceuticals 
that are experimented with and described by enhanced bodybuilders have the potential for 
capturing the imagination and gaining a foothold within the general population. A substance 
such as Cardarine (GW501516), with clinical application in the treatment of diabetes and 
cardiovascular disease, rapidly gained a reputation amongst enhanced bodybuilders for 
weight loss with very few side effects. Provided that the drug’s marketers can gloss over the 
fact that clinical research was discontinued due to its cancer-causing properties, the drug is 
a prime candidate for diffusion to the general population (Mitchell and Bishop-Bailey 2019). 
Similarly, selective androgen receptor modulators (SARMs) promised a highly anabolic 
return for less harm, when compared to anabolic steroids (Basaria, Collins et al. 2013, 
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Narayanan, Ponnusamy et al. 2017) and although not entirely without risk of adverse effects 
(Flores, Chitturi et al. 2020), these drugs may diffuse beyond the enhanced bodybuilder to a 
much wider image-conscious population. 
The products and practices of enhanced bodybuilders are varied and fluid. Clearly, high 
profile exponents have a significant influence within the bodybuilders culture and beyond, 
amongst a wider population of human enhancement drug users and potential users. In 
monitoring these “innovators” and “early adopters” (Rogers 1983, Rogers 1995) we may gain 
an early warning of the potential diffusion of these drug practices to the wider population, 
thereby enabling the rapid development of drug prevention initiatives, harm reduction 
interventions and ultimately health promotion. Significant harm could be averted if the next 
DNP or GHB is anticipated and appropriate responses developed. The trends and practices 
amongst influential enhanced bodybuilders, the dissemination of their experiences, and the 
diffusion of these ideas to the wider AAS using communities should be monitored and 
collated for inclusion in public health activity in the wider population (European Monitoring 
Centre for Drugs and Drug Addiction 2019, Wish, Billing et al. 2020). Central to an effective 
monitoring system is the meaningful engagement and communication with these 
“innovators” and “early adopters” of human enhancement drugs, with the overcoming of   
barriers and mistrust being a pre-requisite to beneficial collaboration (Underwood 2019). The 
trends emanating from this population may provide important intelligence to policy makers 
and public health teams of emerging drug problems in the wider population. 
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